EUS-Guided Celiac Ganglia Neurolysis

Ichiro Yasuda; Shinpei Doi

doi:10.1007/978-981-16-9340-3_21

EUS-Guided Celiac Ganglia Neurolysis

Ichiro Yasuda^*, Shinpei Doi

^*Corresponding author for this work

Internal Medicine （3）

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

EUS-guided celiac ganglia neurolysis (EUS-CGN) is a modified technique of EUS-guided celiac plexus neurolysis (EUS-CPN). In this technique, the celiac ganglia (CG) are punctured and a neurolytic agent is directly injected into them, whereas the agent is injected at the base (the central technique) or on both sides (the bilateral technique) of the celiac axis in EUS-CPN. EUS-CPN and EUS-CGN can be performed for alleviating pain originating from the upper abdominal organs. In particular, their most prominent indication is pancreatic cancer pain, because pain is a common symptom reported in approximately 80% of patients with advanced pancreatic cancer, representing a major issue in the management of patients [1].

Original language	English
Title of host publication	Atlas of Interventional EUS
Subtitle of host publication	Case-based Strategies
Publisher	Springer Nature
Pages	107-109
Number of pages	3
ISBN (Electronic)	9789811693403
ISBN (Print)	9789811693397
DOIs	https://doi.org/10.1007/978-981-16-9340-3_21
State	Published - 2022/01/01

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-981-16-9340-3_21

Cite this

@inbook{70e04b60bc374398a28d6cb96ff896d1,

title = "EUS-Guided Celiac Ganglia Neurolysis",

abstract = "EUS-guided celiac ganglia neurolysis (EUS-CGN) is a modified technique of EUS-guided celiac plexus neurolysis (EUS-CPN). In this technique, the celiac ganglia (CG) are punctured and a neurolytic agent is directly injected into them, whereas the agent is injected at the base (the central technique) or on both sides (the bilateral technique) of the celiac axis in EUS-CPN. EUS-CPN and EUS-CGN can be performed for alleviating pain originating from the upper abdominal organs. In particular, their most prominent indication is pancreatic cancer pain, because pain is a common symptom reported in approximately 80% of patients with advanced pancreatic cancer, representing a major issue in the management of patients [1].",

author = "Ichiro Yasuda and Shinpei Doi",

note = "Publisher Copyright: {\textcopyright} Springer Nature Singapore Pte Ltd. 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-981-16-9340-3_21",

language = "英語",

isbn = "9789811693397",

pages = "107--109",

booktitle = "Atlas of Interventional EUS",

publisher = "Springer Nature",

address = "米国",

}

TY - CHAP

T1 - EUS-Guided Celiac Ganglia Neurolysis

AU - Yasuda, Ichiro

AU - Doi, Shinpei

PY - 2022/1/1

Y1 - 2022/1/1

N2 - EUS-guided celiac ganglia neurolysis (EUS-CGN) is a modified technique of EUS-guided celiac plexus neurolysis (EUS-CPN). In this technique, the celiac ganglia (CG) are punctured and a neurolytic agent is directly injected into them, whereas the agent is injected at the base (the central technique) or on both sides (the bilateral technique) of the celiac axis in EUS-CPN. EUS-CPN and EUS-CGN can be performed for alleviating pain originating from the upper abdominal organs. In particular, their most prominent indication is pancreatic cancer pain, because pain is a common symptom reported in approximately 80% of patients with advanced pancreatic cancer, representing a major issue in the management of patients [1].

AB - EUS-guided celiac ganglia neurolysis (EUS-CGN) is a modified technique of EUS-guided celiac plexus neurolysis (EUS-CPN). In this technique, the celiac ganglia (CG) are punctured and a neurolytic agent is directly injected into them, whereas the agent is injected at the base (the central technique) or on both sides (the bilateral technique) of the celiac axis in EUS-CPN. EUS-CPN and EUS-CGN can be performed for alleviating pain originating from the upper abdominal organs. In particular, their most prominent indication is pancreatic cancer pain, because pain is a common symptom reported in approximately 80% of patients with advanced pancreatic cancer, representing a major issue in the management of patients [1].

UR - http://www.scopus.com/inward/record.url?scp=85163494825&partnerID=8YFLogxK

U2 - 10.1007/978-981-16-9340-3_21

DO - 10.1007/978-981-16-9340-3_21

M3 - 章

AN - SCOPUS:85163494825

SN - 9789811693397

SP - 107

EP - 109

BT - Atlas of Interventional EUS

PB - Springer Nature

ER -

EUS-Guided Celiac Ganglia Neurolysis

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this